Russia Confirms: Production of Sputnik V Vaccine at Torlak to Begin by May
Source: eKapija
Thursday, 25.03.2021.
12:37
Comments
Illustration (Photo: Pixabay.com/Alexey Fedenkov)
Production of Sputnik V is due to start by May 2021 at facilities of the “Torlak” Institute.
– We are grateful to the Government of Serbia for the constant support and trust in Sputnik V. Serbia was among the first countries in the world to approve Sputnik V and use it to protect the population against coronavirus. Production of the Russian vaccine by “Torlak” Institute provides for easier logistics and will also help to speed up the vaccination program in the country – Kirill Dmitriev, CEO of the Russian Direct Investment Fund, said.
Nenad Popovic, Minister of Innovations and Technological Development and Co-Chairman of the Intergovernmental Committee for Cooperation between Serbia and Russia, thanked the President of Russia, Vladimir Putin, the Government of the Russian Federation and the Russian Direct Investment Fund for their support in preserving the health and lives of people in the Republic of Serbia, the press release says.
– The production of the Sputnik V vaccine - adenovirus vaccine coronavirus RDIF at the Torlak Institute will strengthen the capacities of our country to fight against the coronavirus pandemic and open new perspectives for the distribution of this vaccine in the region of Southern Europe. Transfer of technologies for the production of Sputnik V vaccine from Russia to Serbia will contribute to the renewal of our country's sovereignty in the field of vaccine production, which will be an important resource of every country in the future – Popovic said.
Tags:
Russian Direct Investment Fund
RDIF
Institute of Virology Vaccines and Sera Torlak
Torlak
Minister of Innovations and Technological Development of Serbia
Kirill Dmitriev
Nenad Popovic
Sputnik V vaccine
production of Russian vaccine at Torlak
expansion of production capacities
production of Sputnik V
coronavirus
transport of a substance
vial filling
production of the Russian vaccine
Comments
Your comment
Most Important News
Full information is available only to commercial users-subscribers and it is necessary to log in.
Follow the news, tenders, grants, legal regulations and reports on our portal.
Registracija na eKapiji vam omogućava pristup potpunim informacijama i dnevnom biltenu
Naš dnevni ekonomski bilten će stizati na vašu mejl adresu krajem svakog radnog dana. Bilteni su personalizovani prema interesovanjima svakog korisnika zasebno,
uz konsultacije sa našim ekspertima.